Literature DB >> 12057116

Adrenal cortical carcinoma.

R P Boushey1, A P Dackiw.   

Abstract

Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor--the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12057116     DOI: 10.1007/s11864-001-0029-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  42 in total

Review 1.  Hormonal evaluation of the patient with an incidentally discovered adrenal mass.

Authors:  N S Ross; D C Aron
Journal:  N Engl J Med       Date:  1990-11-15       Impact factor: 91.245

2.  Laparoscopic adrenalectomy for nonmalignant disease: improved safety, morbidity, and cost-effectiveness.

Authors:  S R Schell; M A Talamini; R Udelsman
Journal:  Surg Endosc       Date:  1999-01       Impact factor: 4.584

3.  Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis.

Authors:  S Gröndal; B Cedermark; B Eriksson; L Grimelius; R Harach; A Kristoffersson; J Rastad; P Udén; G Akerström
Journal:  Eur J Surg Oncol       Date:  1990-12       Impact factor: 4.424

4.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.

Authors:  R Vassilopoulou-Sellin; V F Guinee; M J Klein; S H Taylor; K R Hess; P N Schultz; N A Samaan
Journal:  Cancer       Date:  1993-05-15       Impact factor: 6.860

5.  Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.

Authors:  A Berruti; M Terzolo; A Pia; A Angeli; L Dogliotti
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

6.  Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.

Authors:  J Zidan; M Shpendler; E Robinson
Journal:  Am J Clin Oncol       Date:  1996-06       Impact factor: 2.339

7.  Suramin in adrenocortical cancer: limited efficacy and serious toxicity.

Authors:  W Arlt; M Reincke; L Siekmann; W Winkelmann; B Allolio
Journal:  Clin Endocrinol (Oxf)       Date:  1994-09       Impact factor: 3.478

8.  Survival rates and prognostic factors in adrenocortical carcinoma.

Authors:  P Icard; A Louvel; Y Chapuis
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

9.  Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.

Authors:  A Berruti; M Terzolo; P Paccotti; F Veglio; A Pia; L Dogliotti; A Angeli
Journal:  Tumori       Date:  1992-10-31

10.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

Authors:  H R Haak; J Hermans; C J van de Velde; E G Lentjes; B M Goslings; G J Fleuren; H M Krans
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more
  3 in total

Review 1.  Diagnosis and management of adrenal cortical carcinoma.

Authors:  Brant R Fulmer
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

2.  A rare cause of secondary hypertension.

Authors:  Chin-Chi Kuo; Vin-Cent Wu; Ching-Wei Tsai; Fan-Fen Wang; Shih-Chieh Chueh; Kwan-Dun Wu
Journal:  NDT Plus       Date:  2009-01-28

3.  Identification of Five Genes as a Potential Biomarker for Predicting Progress and Prognosis in Adrenocortical Carcinoma.

Authors:  He Xiao; Deqiang Xu; Ping Chen; Guang Zeng; Xinghuan Wang; Xinhua Zhang
Journal:  J Cancer       Date:  2018-10-31       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.